Association of rs4711998 of IL-17A, rs2275913 of IL-17A and rs763780 IL-17F gene polymorphisms with non-segmental vitiligo in a Mexican population

• Published in: Archives of dermatological research 2023-04, Vol.315 (3), p.447-454
• Main Authors: Zapata-Salazar, Natalia Aranza, Kubelis-Lopez, David Emmanuel, Salinas-Santander, Mauricio Andres, Sanchez-Dominguez, Celia Nohemi, Xolalpa-Rosales, Ana Cecilia, Gomez-Galindo, Marely Eugenia, Ocampo-Candiani, Jorge
• Format: Article
• Language: English
• Subjects: Apoptosis; Case-Control Studies; CD4 antigen; CD8 antigen; Cytotoxicity; Dermatology; Gene polymorphism; Genetic Predisposition to Disease; Genotype; Genotyping; Humans; Hypopigmentation; Immune system; Interleukin 17; Interleukin-17 - genetics; Lymphocytes T; Medicine; Medicine & Public Health; Melanocytes; Original Paper; Pathogenesis; Polymerase chain reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Restriction fragment length polymorphism; Risk factors; Single-nucleotide polymorphism; Vitiligo; Vitiligo - epidemiology; Vitiligo - genetics
• ISSN: 1432-069X; 0340-3696; 1432-069X
• DOI: 10.1007/s00403-022-02382-8

Vitiligo is the most common depigmenting disease characterized by achromic macules due to selective loss of melanocytes. The pathogenesis remains poorly elucidated, and multiple hypotheses exist regarding its pathogenesis. Evidence suggests that stress on melanocytes can result in activation of the immune system, and involvement of both activated cluster of differentiation (CD8+) cytotoxic and CD4+ T cells in the dysfunction, depigmentation, and apoptosis of melanocytes. Recent studies show that the interleukin 17 (IL-17) axis plays a central role in the pathogenesis of the disease. IL-17 is an important regulatory effector cytokine in this pathway. The aim of this study was to evaluate the association of IL-17A rs4711998 (−832A/G), IL-17A rs2275913 (−197G/A), and IL-17F rs763780 (7488A/G) with vitiligo in a Northeastern Mexican population. This was a case–control study and included 116 patients with vitiligo and 116 control subjects. Genotype characterization of IL-17A rs4711998 (−832A/G), IL-17A rs2275913 (−197G/A), and IL-17F rs763780 (7488A/G) was performed using polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) method. A p  ≤ 0.05 was considered significant. It was observed that the combination of the genotypes GG/GA for IL-17F rs763780 (7488A/G) was associated with an increased risk for the development of vitiligo (OR 2.0943, 95% Cl 1.2375–3.5445, p  = 0.0056). Regarding IL-17A rs4711998 (−832A/G) and IL-17A rs2275913 (−197G/A) genotyping, no association with vitiligo development was found. In conclusion, the SNP rs763780 in the IL-17F gene appears to be a risk factor for vitiligo development in this Mexican population and it may be useful in future studies, especially for the development of new therapies.